USP15 inhibition is one of the key to preventing and reversing multiple sclerosis

About Us

Corbin Therapeutics is a Montreal-based biotech company, using a unique drug discovery platform to identify and develop novel USP15 inhibitors for treatment of various inflammation diseases, such as multiple sclerosis. This platform includes several in-vitro and in-vivo models for efficient drug screening and confirmation of potential lead candidates.

Latest News